Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Rating) in a report issued on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

APVO has been the subject of several other reports. TheStreet raised Aptevo Therapeutics from a d rating to a c- rating in a research note on Friday, August 26th. Piper Sandler reduced their price objective on Aptevo Therapeutics from $20.00 to $13.00 in a research note on Friday, August 12th.

Aptevo Therapeutics Stock Down 7.7 %

Shares of NASDAQ APVO opened at $2.88 on Monday. The stock has a fifty day moving average price of $3.07 and a two-hundred day moving average price of $3.73. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.12. Aptevo Therapeutics has a 1 year low of $2.67 and a 1 year high of $22.08.

Institutional Trading of Aptevo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Cantor Fitzgerald L. P. acquired a new stake in shares of Aptevo Therapeutics in the third quarter worth $406,000. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics in the third quarter worth $51,000. Virtu Financial LLC boosted its position in shares of Aptevo Therapeutics by 122.6% in the third quarter. Virtu Financial LLC now owns 28,421 shares of the biotechnology company’s stock worth $86,000 after buying an additional 15,653 shares during the period. Renaissance Technologies LLC boosted its position in shares of Aptevo Therapeutics by 18.7% in the second quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock worth $250,000 after buying an additional 11,000 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Aptevo Therapeutics by 7.3% in the first quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock worth $1,414,000 after buying an additional 16,337 shares during the period. Institutional investors and hedge funds own 15.63% of the company’s stock.

Aptevo Therapeutics Company Profile

(Get Rating)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.

Recommended Stories

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.